FDA Extends Wyeth, Progenics NDA Review For Methylnaltrexone Until April
This article was originally published in The Pink Sheet Daily
Executive Summary
Additional three months of review will push methylnaltrexone action date behind GSK/Adolor’s Entereg.
You may also be interested in...
Wyeth/Progenics’ Relistor: FDA Says Yes, EU Likes It, Too
Compound helps bowel function in dying patients on opioids.
Wyeth/Progenics’ Relistor: FDA Says Yes, EU Likes It, Too
Compound helps bowel function in dying patients on opioids.
Daily Cost of Wyeth’s Pristiq For Depression Beats Effexor By 20 Percent
50 mg and 100 mg Pristiq tablets will be sold for a flat rate of $3.41, firm announces during an April 22 first quarter sales and earnings call.